Skip to main content
Top
Published in: Endocrine 2/2012

01-10-2012 | Editorial

Non-alcoholic fatty liver, adipose tissue, and the bone: a new triumvirate on the block

Author: Giovanni Musso

Published in: Endocrine | Issue 2/2012

Login to get access

Excerpt

In the latest years, a growing body of evidence has connected metabolic syndrome and obesity to bone loss and osteoporosis [1], thereby challenging the conventional view that excessive body weight protects against osteoporosis through increased mechanical load to the skeleton and enhanced cortical bone deposition [2]. In a parallel way, available data suggest that excess body weight may be detrimental to the skeleton, and that excessive adipose tissue plays a key role in this relationship [3]. Within this frame of research, recent studies focused on the relationship between bone health and non-alcoholic fatty liver (NAFLD), the hepatic manifestation of the metabolic syndrome, which recognizes in altered adipose tissue adipokine secretion a key pathogenic factor [4]. The two published studies on endocrine add importantly to the existing literature on the association between NAFLD and osteoporosis. First, ultrasonographic NAFLD was linked to low bone mass in a large cohort of Korean postmenopausal women, independently of age, BMI, smoking status, alcohol intake, and metabolic syndrome [5]. Second, the effect of a multidisciplinary weight-losing regimen on NAFLD, bone mineral density (BMD), and adipokine profile was assessed in post-puberal obese adolescents: weight loss improved NAFLD, BMD, insulin resistance, and plasma lipids. Importantly, bone mineral content changes were related to a reduction in insulin resistance and plasma leptin levels [6]. Consistent with these data, a recent cross-sectional study, connected the histological severity of NAFLD to the degree of BMD changes in obese children [7]. …
Literature
1.
go back to reference D. von Muhlen, S. Safii, S.K. Jassal, J. Svartberg, E. Barrett-Connor, Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos. Int. 18, 1337–1344 (2007)CrossRef D. von Muhlen, S. Safii, S.K. Jassal, J. Svartberg, E. Barrett-Connor, Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos. Int. 18, 1337–1344 (2007)CrossRef
2.
go back to reference F.J.A. de Paula, M.C. Horowitz, C.J. Rosen, Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26, 622–630 (2010)PubMedCrossRef F.J.A. de Paula, M.C. Horowitz, C.J. Rosen, Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26, 622–630 (2010)PubMedCrossRef
3.
go back to reference C.B. Confavreux, Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. 79(Suppl 121), S14–S19 (2011)CrossRef C.B. Confavreux, Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int. 79(Suppl 121), S14–S19 (2011)CrossRef
4.
go back to reference G. Musso, R. Gambino, M. Cassader, G. Pagano, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649 (2011)PubMedCrossRef G. Musso, R. Gambino, M. Cassader, G. Pagano, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649 (2011)PubMedCrossRef
6.
go back to reference R.M. Campos, A. de Piano, P.L. da Silva, J. Carnier, P.L. Sanches, F.C. Corgosinho et al., The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine (2012). doi:10.1007/s12020-012-9613-3 PubMed R.M. Campos, A. de Piano, P.L. da Silva, J. Carnier, P.L. Sanches, F.C. Corgosinho et al., The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine (2012). doi:10.​1007/​s12020-012-9613-3 PubMed
7.
go back to reference P.E. Pardee, W. Dunn, J.B. Schwimmer, Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment. Pharmacol. Ther. 35, 248–254 (2012)PubMedCrossRef P.E. Pardee, W. Dunn, J.B. Schwimmer, Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. Aliment. Pharmacol. Ther. 35, 248–254 (2012)PubMedCrossRef
8.
go back to reference K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37, 11–32 (2010)PubMedCrossRef K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37, 11–32 (2010)PubMedCrossRef
9.
go back to reference G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)PubMedCrossRef
10.
go back to reference K. Fulzele, R.C. Riddle, D.J. Digirolamo, X. Cao, C. Wan, D. Chen et al., Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309–319 (2010)PubMedCrossRef K. Fulzele, R.C. Riddle, D.J. Digirolamo, X. Cao, C. Wan, D. Chen et al., Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309–319 (2010)PubMedCrossRef
11.
go back to reference G. Musso, M. Cassader, F. Rosina, R. Gambino, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885–904 (2012)PubMedCrossRef G. Musso, M. Cassader, F. Rosina, R. Gambino, Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 55, 885–904 (2012)PubMedCrossRef
12.
go back to reference S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006)PubMedCrossRef S.E. Kahn, S.M. Haffner, M.A. Heise, W.H. Herman, R.R. Holman, N.P. Jones et al., Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006)PubMedCrossRef
13.
go back to reference T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi et al., Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784–788 (2009)PubMedCrossRef T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi et al., Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone 45, 784–788 (2009)PubMedCrossRef
14.
go back to reference A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, R.L. Jilka, Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226–1235 (2005)PubMedCrossRef A.A. Ali, R.S. Weinstein, S.A. Stewart, A.M. Parfitt, S.C. Manolagas, R.L. Jilka, Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146, 1226–1235 (2005)PubMedCrossRef
15.
go back to reference L.R. McCabe, Understanding the pathology and mechanisms of type 1 diabetic bone loss. J. Cell. Biochem. 102(6), 1343–1357 (2007)PubMedCrossRef L.R. McCabe, Understanding the pathology and mechanisms of type 1 diabetic bone loss. J. Cell. Biochem. 102(6), 1343–1357 (2007)PubMedCrossRef
16.
go back to reference M.L. Olson, N.M. Maalouf, J.D. Oden, P.C. White, M.R. Hutchison, Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J. Clin. Endocrinol. Metab. 97(1), 279–285 (2012)PubMedCrossRef M.L. Olson, N.M. Maalouf, J.D. Oden, P.C. White, M.R. Hutchison, Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J. Clin. Endocrinol. Metab. 97(1), 279–285 (2012)PubMedCrossRef
17.
18.
go back to reference A. Birendinc, M. Abawi, M. Stepanova, A. Afendy, A. Baranova, Z. Goodman et al., Vitamin D may be protective against apoptosis in patients with nonalcoholic steatohepatitis (NASH). J. Hepatol. 56(S2), S501–S502 (2012)CrossRef A. Birendinc, M. Abawi, M. Stepanova, A. Afendy, A. Baranova, Z. Goodman et al., Vitamin D may be protective against apoptosis in patients with nonalcoholic steatohepatitis (NASH). J. Hepatol. 56(S2), S501–S502 (2012)CrossRef
19.
go back to reference M. Mahmud, I. Abdullah, R. Ghantous, J. Amer, Low vitamin D levels in nonalcoholic fatty liver disease associate with insulin resistance and liver injury progression via immune NK mechanisms. J. Hepatol. 56(S2), S503 (2012)CrossRef M. Mahmud, I. Abdullah, R. Ghantous, J. Amer, Low vitamin D levels in nonalcoholic fatty liver disease associate with insulin resistance and liver injury progression via immune NK mechanisms. J. Hepatol. 56(S2), S503 (2012)CrossRef
20.
go back to reference D. Kim, G.E. Chung, S.H. Lim, J.I. Yim, M.J. Park, Serum vitamin D is inversely associated with nonalcoholic fatty liver disease in general population. J. Hepatol. 56(S2), S511 (2012) D. Kim, G.E. Chung, S.H. Lim, J.I. Yim, M.J. Park, Serum vitamin D is inversely associated with nonalcoholic fatty liver disease in general population. J. Hepatol. 56(S2), S511 (2012)
21.
go back to reference N.C. Bozkurt, E. Cakal, M. Sahin, E.C. Ozkaya, H. Firat, T. Delibasi, The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41, 518–525 (2012)PubMedCrossRef N.C. Bozkurt, E. Cakal, M. Sahin, E.C. Ozkaya, H. Firat, T. Delibasi, The relation of serum 25-hydroxyvitamin-D levels with severity of obstructive sleep apnea and glucose metabolism abnormalities. Endocrine 41, 518–525 (2012)PubMedCrossRef
22.
go back to reference T. Nakano, Y.F. Cheng, C.Y. Lai, L.W. Hsu, Y.C. Chang, J.Y. Deng et al., Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J. Hepatol. 55, 415–425 (2011)PubMedCrossRef T. Nakano, Y.F. Cheng, C.Y. Lai, L.W. Hsu, Y.C. Chang, J.Y. Deng et al., Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J. Hepatol. 55, 415–425 (2011)PubMedCrossRef
Metadata
Title
Non-alcoholic fatty liver, adipose tissue, and the bone: a new triumvirate on the block
Author
Giovanni Musso
Publication date
01-10-2012
Publisher
Springer US
Published in
Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9748-2

Other articles of this Issue 2/2012

Endocrine 2/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.